SecBot SecBot
S-4 ·Filed Sep 1, 2026

FULC

Fulcrum Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001193125-26-379106
Notable filing: S-4
Actionable Insight ▼ Bearish

The S-4 confirms Fulcrum is being acquired for its net cash and public listing, not its pipeline. The ~$270M special dividend provides a near-term cash return, but the 5% pro forma ownership stake means existing Fulcrum shareholders will have negligible ongoing exposure to Slate's migraine programs. Monitor the stockholder vote and any potential competing bids; the low valuation of Fulcrum ($31.3M) relative to its ~$318.8M cash position suggests the market may have already priced in a liquidation discount.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.85
T+0 close · Sep 1, 2026 · via day close
Latest settled
−3.90%
T+20 · $3.70 · next T+60 in 10d
Vs SPY
−3.57%
α at T+20
Latest observation
+19.26%
T+52 · FF3 residual α
  1. T+0 · Sep 2 $3.85entry
  2. T+1 · 3mo ago −0.26%α −1.31% · $3.84
  3. T+5 · 2mo ago −1.30%α −0.34% · $3.80
  4. T+20 · 7w ago −3.90%α −3.57% · $3.70
  5. T+52 · todayOpen
  6. T+60 · in 10d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines. Under the agreement, pre-merger Slate stockholders (excluding concurrent investors) will own ~55.9% of the combined company, new investors in a concurrent $245M investment will own ~39.1%, and pre-merger Fulcrum stockholders will own only ~5.0% on a fully diluted basis. Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270M, but their equity stake in the combined entity is minimal, making this effectively a sale of Fulcrum's public shell and net cash to Slate.

Key Facts

  • Pre-merger Fulcrum stockholders will own only ~5.0% of the combined company on a fully diluted basis.
  • Pre-merger Slate stockholders (excluding investors) will own ~55.9%, and new investors in a $245M concurrent investment will own ~39.1%.
  • Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270 million.
  • Fulcrum's valuation is assumed at $31.3M, subject to downward adjustment if net cash at closing is less than $20.3M.
  • Fulcrum has discontinued its pociredir program and reduced its workforce by ~85% to nine employees.
  • The combined company will be renamed Slate Medicines, Inc. and trade under the symbol SLTE.
  • Slate's lead candidate, SLTE-1009, is a clinical-stage bispecific antibody targeting PACAP/VIP for migraine prevention.
  • Fulcrum's board recommends voting FOR all proposals, including the stock issuance and reverse stock split.

Financial Impact

Fulcrum stockholders' ownership diluted to ~5% of combined entity; special dividend of ~$270M to be distributed to pre-merger Fulcrum holders.

dilutionownershipcash

Risk Factors

  • Stockholder approval may not be obtained, causing the merger to fail and Fulcrum to pursue a potentially less favorable liquidation.
  • The exchange ratio is fixed and does not adjust for Fulcrum's stock price, creating value uncertainty for Slate stockholders.
  • Slate's lead candidate SLTE-1009 is early-stage and unproven in humans, with no anti-PACAP therapy ever approved.
  • The combined company will need substantial additional capital beyond the $245M concurrent investment to fund development.
  • Fulcrum's remaining nine employees may be insufficient to manage the merger process and regulatory obligations.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-4 Filing (Primary)0001193125-26-379106
Document: d127837dex1014.htm0001193125-26-379106

Track record

23 reports on FULC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026